Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits. We evaluated the efficacy and safety of rapid, peripheral, high-dose cyclophosphamide (TurboCy) in 15 patients intending to proceed with CAR T-cell therapy, BsAbs, or long-term regimens. The overall response rate was 80% and the clinical benefit rate was 100% in a heavily pretreated high-risk cohort. Cytopenias were common but no deaths occurred during bridging. All patients proceeded to their next line of intended therapy. TurboCy is an effective and safe bridging strategy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647735PMC
http://dx.doi.org/10.1002/jha2.1039DOI Listing

Publication Analysis

Top Keywords

high-dose cyclophosphamide
8
multiple myeloma
8
car t-cell
8
t-cell therapy
8
rapid high-dose
4
bridging
4
cyclophosphamide bridging
4
bridging treatment
4
treatment advanced
4
advanced therapies
4

Similar Publications

This study aims to establish the S_(180) tumor-bearing mice model, and to investigate the influence of Shenqi Erpi Granules(SQEPG) on immune function, as well as the drug's tumor-suppressive effect and mechanism. SPF grade KM mice(half male and half female) were randomly divided into 6 groups: a control group, a model group, a cyclophosphamide group(50 mg·kg~(-1)), as well as SQEPG groups in low-, medium-, and high-dose(5.25, 10.

View Article and Find Full Text PDF

BACKGROUND Pericarditis is a frequently encountered complication of systemic lupus erythematosus (SLE). However, cardiac tamponade resulting from massive pericardial effusion is a rare sequela. Risk factors for cardiac tamponade in SLE include female sex, reduced serum complement, and positive anti-nucleosome antibody at diagnosis.

View Article and Find Full Text PDF

Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation.

Haematologica

August 2025

Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM U1342, Saint Louis Research Institute, IHU Leukemia Institute Paris Saint Louis, SIRIC InSitu, Paris Cité University, Paris.

Allogeneic hematopoietic stem cell transplantation (alloHSCT) from mismatched unrelated donors (MMUD) carries high risks of non-relapse mortality (NRM) and graft-versus-host disease (GVHD). Post-transplant cyclophosphamide (PTCY) has emerged as an alternative to antithymocyte globulin (ATG) for GVHD prophylaxis. This single-center retrospective study compared PTCY (n=41) to high-dose ATG and low-dose ATG in 155 MMUD alloHSCT recipients.

View Article and Find Full Text PDF

Rationale: Behçet disease (BD) is a chronic inflammatory vasculitis that primarily affects young males and is associated with severe vascular complications. Prolonged nonsteroidal anti-inflammatory drug (NSAID) use may mask early inflammatory signs, delaying diagnosis and appropriate treatment.

Patient Concerns: A 28-year-old pharmacist experienced syncope, chest pain, and leg swelling after prolonged NSAID use.

View Article and Find Full Text PDF

BK virus-associated cystitis/urethritis (BK-C) is a major cause of morbidity in allogeneic hematopoietic cell transplantation (HCT) recipients. We prospectively followed weekly plasma and urine BK viral loads and associated symptoms in 169 recipients of post-transplantation cyclophosphamide (PTCy)-based HCT. Patients with ≥2 positive BK specimens before day +100 were considered at-risk for developing BK-C.

View Article and Find Full Text PDF